|
122
|
| 679 |
EDN1
|
|
decreases_activity of
|
GSK3B
|
in myocytes; by phosphorylation of GSK3B at Ser9
|
| 680 |
EDN1
|
|
increases_phosphorylation of
|
GSK3B
|
at Ser9, hereby inhibiting GSK3B.
|
|
11527574
|
Alzheimer disease
|
|
2,104
|
| 17599 |
Major depressive disorder
|
|
decreases_quantity of
|
EDN1
|
|
|
20161799
|
Major depressive disorder
|
|
2,525
|
| 23522 |
EDN1
|
NOT |
decreases_quantity of
|
Amyloid beta peptide
|
|
| 23530 |
EDN1
|
|
decreases_expression of
|
CCL2
|
if Abeta-induced expression
|
| 23533 |
EDN1
|
|
decreases_expression of
|
IL6
|
if Abeta-induced expression
|
| 23549 |
EDN1
|
|
affects_activity of
|
inflammatory response
|
|
|
20937084
|
Alzheimer disease
|
|
2,547
|
| 23729 |
Schizophrenia
|
|
affects_quantity of
|
EDN1
|
|
|
20520744
|
Schizophrenia
|
|
4,736
|
| 46855 |
EDN1
|
|
interacts (colocalizes) with
|
EDNRA
|
|
| 46856 |
EDN1
|
|
interacts (colocalizes) with
|
EDNRB
|
|
| 47038 |
EDN1
|
|
increases_quantity of
|
NOS3
|
via activation of ETB receptors and PI3K
|
| 47039 |
EDN1
|
|
increases_quantity of
|
NO
|
via activation of ETB receptors and PI3K
|
| 50712 |
EDN1
|
|
increases_expression of
|
NOS3
|
via activation of ETB receptors and PI3K
|
|
15113749
|
Cardiovascular disease
|
|
4,737
|
| 46857 |
EDN1
|
|
increases_expression of
|
NOS3
|
via ETA receptors (EDNRA)
|
|
10519149
|
Cardiovascular disease
|
|
4,739
|
| 46868 |
sFLT1
|
|
increases_expression of
|
EDN1
|
in presence of TNF-alpha
|
|
21139021
|
Preeclampsia/eclampsia 1
Cardiovascular disease
|
|
4,741
|
| 46886 |
NO
|
|
decreases_expression of
|
EDN1
|
|
| 46887 |
sFLT1
|
|
increases_expression of
|
EDN1
|
in kidney
|
|
22282588
|
Preeclampsia/eclampsia 1
Cardiovascular disease
|
|
4,747
|
| 47008 |
NO
|
|
decreases_quantity of
|
EDN1
|
in endothelial cells
|
|
2153712
|
Metabolic
Cardiovascular disease
|
|
4,749
|
| 47033 |
ECE1
|
|
increases_processing of
|
EDN1
|
|
|
9396733
|
Metabolic
Cardiovascular disease
|
|
4,750
|
| 47034 |
EDN1
|
|
interacts (colocalizes) with
|
EDNRA
|
|
| 47035 |
EDN1
|
|
interacts (colocalizes) with
|
EDNRB
|
|
|
7672512
|
Metabolic
Cardiovascular disease
|
|
4,971
|
| 49151 |
EDN1
|
|
increases_activity of
|
foam cell differentiation
|
in rat bone marrow-derived macrophages
|
| 49152 |
EDN1
|
|
decreases_quantity of
|
ABCG1
|
in rat bone marrow-derived macrophages
|
| 49156 |
EDN1
|
|
decreases_activity of
|
cholesterol efflux
|
in rat bone marrow-derived macrophages
|
| 49158 |
EDN1
|
NOT |
affects_expression of
|
ABCG1
|
in rat bone marrow-derived macrophages
|
| 49159 |
EDN1
|
|
increases_activity of
|
EDNRA
|
in rat bone marrow-derived macrophages
|
| 49160 |
EDN1
|
|
increases_activity of
|
EDNRB
|
in rat bone marrow-derived macrophages
|
| 49179 |
EDN1
|
|
increases_activity of
|
Calpain
|
in rat bone marrow-derived macrophages
|
| 49183 |
EDN1
|
NOT |
affects_quantity of
|
CD36
|
in rat bone marrow-derived macrophages
|
| 49184 |
EDN1
|
NOT |
affects_quantity of
|
SCARB1
|
in rat bone marrow-derived macrophages
|
| 49185 |
EDN1
|
NOT |
affects_quantity of
|
MSR1
|
in rat bone marrow-derived macrophages
|
| 49186 |
EDN1
|
NOT |
affects_quantity of
|
ABCA1
|
in rat bone marrow-derived macrophages
|
|
21520072
|
Cardiovascular disease
Atherosclerosis
|
|
5,012
|
| 49444 |
OLR1
|
|
increases_expression of
|
EDN1
|
|
| 49452 |
OLR1
|
|
increases_quantity of
|
EDN1
|
|
| 49453 |
CD40 signaling pathway
|
|
increases_expression of
|
EDN1
|
|
| 49454 |
CD40 signaling pathway
|
|
increases_quantity of
|
EDN1
|
|
|
15838273
|
Cardiovascular disease
Atherosclerosis
|
|
5,884
|
| 55621 |
pulmonary hypertension
|
|
increases_expression of
|
EDN1
|
in lung
|
|
24124488
|
Pulmonary hypertension
Lung disease
|
|
5,909
|
| 55793 |
EDN1
|
|
decreases_activity of
|
vasodilation
|
|
| 55794 |
response to hypoxia
|
|
increases_expression of
|
EDN1
|
|
| 55796 |
PGF
|
|
increases_expression of
|
EDN1
|
in a dermal microvascular endothelial cell line (HMEC-1)
|
| 55808 |
mir-648
|
|
decreases_expression of
|
EDN1
|
in endothelial cells
|
| 55809 |
mir-648
|
|
decreases_quantity of
|
EDN1
|
in endothelial cells
|
|
25403488
|
Osteoarthritis
Sickle cell anemia
|
|
6,150
|
| 57541 |
hyperglycemia
|
|
increases_expression of
|
EDN1
|
in left ventricular myocardium; under poor hyperglycemic control
|
|
19367030
|
Diabetes mellitus, type II
Insulin resistance
Cardiomyopathy, diabetic
|
|
7,140
|
| 70308 |
GLIS2
|
|
affects_expression of
|
EDN1
|
|
|
|
Nephronophthisis 7
Ciliopathy
|
|
10,043
|
| 104849 |
CASZ1
|
|
affects_expression of
|
EDN1
|
in heart
|
|
25190801
|
Cardiovascular disease
Chromosome 1p36 deletion syndrome
|
|
10,316
|
| 107080 |
Monocrotaline
|
|
increases_expression of
|
EDN1
|
|
| 107085 |
EDN1
|
|
increases_expression of
|
NOX4
|
in pulmonary artery smooth muscle cells
|
| 107086 |
EDN1
|
|
decreases_expression of
|
GPX1
|
in pulmonary artery smooth muscle cells
|
| 107087 |
EDN1
|
|
increases_quantity of
|
Reactive oxygen species
|
in pulmonary artery smooth muscle cells
|
|
30274504
|
Pulmonary hypertension
|
|
12,012
|
| 117683 |
EDN1
|
NOT |
increases_activity of
|
exosomal secretion
|
in cardiac fibroblasts
|
|
26497614
|
Cardiovascular disease
|
|
12,064
|
| 118451 |
AGTR1
|
|
increases_activity of
|
EDN1
|
|
|
19065996
|
Diabetes mellitus, type II
Insulin resistance
|
|
12,362
|
| 121218 |
Angiotensin (1-7)
|
|
affects_activity of
|
EDN1
|
|
|
24450744
|
Diabetes mellitus, type II
Insulin resistance
|
|
12,465
|
| 121623 |
UCN3
|
|
decreases_quantity of
|
EDN1
|
in blood plasma; in experimental heart failure
|
|
16825287
|
Cardiovascular disease
|
|
13,337
|
| 125877 |
SARS-CoV-2 infection
|
|
affects_expression of
|
EDN1
|
|
|
|
COVID-19
|
|
13,459
|
| 126847 |
Nephropathy, diabetic, progressive
|
|
increases_expression of
|
EDN1
|
in kidney; via NF-kappaB
|
|
17065335
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
14,073
|
| 132995 |
ACE2
|
|
decreases_expression of
|
EDN1
|
|
|
29570986
|
Cardiovascular disease
|
|
14,302
|
| 134966 |
EDN1
|
|
decreases_expression of
|
ACE2
|
in cardiac myocytes
|
| 134995 |
EDN1
|
|
decreases_activity of
|
Angiotensin (1-7)
|
via ERK1/ERK2 signaling
|
|
32305401
|
Cardiovascular disease
COVID-19
|
|
14,345
|
| 135302 |
MB
|
|
increases_expression of
|
EDN1
|
in kidney
|
|
21249398
|
Chronic kidney disease
|
|
15,281
|
| 144514 |
EDN1
|
|
increases_activity of
|
regulation of maintenance of permeability of blood-brain barrier
|
|
| 144515 |
EDN1
|
|
affects_activity of
|
diapedesis
|
of monocytes, across the human endothelium
|
| 144516 |
EDN1
|
|
increases_activity of
|
abnormal blood-brain barrier function
|
after transient middle artery occlusion
|
| 144517 |
Amyloid beta peptide (oligomer)
|
|
increases_expression of
|
EDN1
|
causing capillary vasoconstriction and altering AQP4 distribution
|
| 144519 |
EDN1
|
|
increases_activity of
|
response to oxidative stress
|
after transient middle artery occlusion
|
| 144549 |
EDN1
|
|
affects_activity of
|
Alzheimer disease
|
|
|
|
Alzheimer disease
|
|
15,285
|
| 144572 |
Alzheimer disease
|
|
increases_quantity of
|
EDN1
|
a pericyte marker
|
|
|
Alzheimer disease
|
CIDeRplus